Clinical trials: Acute Treatment of Migraine
Migraine With Aura
Efficacy and Safety of TMS for the Preemptive Treatment of Migraine With Aura
Assess safety and efficacy of Transcranial Magnetic Stimulation (TMS) for the treatment of migraine with aura The hypothesis is that TMS treatments delivered to the occipital cortex of the brain can stop or interrupt the…
- Trial name
- NCT00449540
- Testing
- Active Transcranial Magnetic Stimulation (TMS) Device
- Where
- 14 sites in United States
- Volunteers
- 201 people
- Sponsor
- Neuralieve
Migraine
Single-Site Study of Naltrexone/Acetaminophen for the Acute Treatment of Migraine: A Phase 2 Randomized Trial
This two-stage clinical trial will assess a novel combination therapy for acute migraine. In Stage 1 (factorial), participants will receive the combination, each individual component, or placebo.
- Trial name
- AT-06 (NCT05685225)
- Testing
- Stage 1: Naltrexone/Acetaminophen, Stage 1: Naltrexone, Stage 1: Acetaminophen
- Where
- United States
- Sponsor
- Allodynic Therapeutics, Inc
Migraine With Typical Aura
Study With Migraid Device in Acute, Early Treatment of Migraine With Typical Aura
The purpose of the study was to assess the efficacy of Migraid in terms of preventing headaches in patients with migraine with typical aura.
- Trial name
- NCT00126035
- Testing
- Migraid
- Where
- Netherlands
- Volunteers
- 134 people
- Sponsor
- Profess Medical Consultancy
Migraine
Comparison of Patient-reported Outcomes for Rimegepant and Triptans in the 2023 US National Health and Wellness Survey
This is a cross-sectional study using the cross-sectional 2023 National Health and Wellness Survey (NHWS) data from the US, with a large and nationally representative population (N=75,007).
- Trial name
- NCT06680206
- Testing
- Rimegepant, Triptans
- Where
- United States
- Volunteers
- 1,395 people
- Sponsor
- Pfizer
Migraine Disorders, Heart Disease
Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)
The purpose of this study is to evaluate the safety and efficacy of telcagepant in the treatment of acute migraine in participants with stable vascular disease.
- Conditions
- Migraine Disorders, Heart Disease, Cerebrovascular Accident, TIA (Transient Ischemic Attack)
- Trial name
- NCT00662818
- Testing
- Telcagepant, Acetaminophen/Paracetamol
- Volunteers
- 165 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Migraine
Safety and Efficacy Trial of BHV3000 (Rimegepant) 75 mg for the Acute Treatment of Migraine
This trial is to determine whether BHV3000 (rimegepant) 75mg is safe and effictive as a treatment for acute migraine in Chinese and Korean patients
- Trial name
- NCT04574362
- Testing
- Rimegepant
- Where
- 90 sites in China, South Korea
- Volunteers
- 1,648 people
- Sponsor
- Pfizer
Migraine
Post-marketing Clinical Trial of Elexir(Trigeminal Nerve Electrical Stimulator) for the Acute Treatment of Migraine
The purpose of this study is to evaluate the efficacy and safety of treating migraine in the acute phase by applying the acute mode (program 1) of Elexir (trigeminal nerve electrical stimulator) to patients with migraine.
- Trial name
- NCT06170411
- Testing
- Elexir (program1)
- Where
- 2 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Nu Eyne Co., Ltd.
Migraine With or Without Aura
Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine
The study consists of a screening visit, out-patient treatment of a moderate or severe migraine attack with a single dose of the study medication within 8 weeks, and End-of-Study Visit 2-7 days after dosing.
- Trial name
- ANODYNE-1 (NCT03061734)
- Testing
- Naltrexone and Acetaminophen, Naltrexone and Acetaminophen-High Dose, Naltrexone Alone (regular dose)
- Where
- United States
- Volunteers
- 92 people
- Sponsor
- Allodynic Therapeutics, Inc
Migraine
Hydromorphone Versus Prochlorperazine + Diphenhydramine for Acute Migraine
Opioids are commonly used to treat migraine in North American Emergency Departments. We are comparing efficacy and adverse events of hydromorphone, an opioid, to that of prochlorperazine, a dopamine antagonist with known efficacy…
- Trial name
- NCT02389829
- Testing
- Hydromorphone, Prochlorperazine, Diphenhydramine
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- Montefiore Medical Center
Migraine Disorders
Reliability of Rimegepant or Triptans for the Acute Treatment of Migraine
This protocol describes the analysis of the Adelphi Real World (ARW) Migraine Disease Specific Programme(TM) 2022, a cross-sectional study which used both physician and patient surveys to assess the perception of the acute…
- Trial name
- Adelphi DSP (NCT06412965)
- Where
- United States
- Volunteers
- 528 people
- Sponsor
- Pfizer
Acute Migraine
Long-term Safety Study of BHV-3500 (Zavegepant*) for the Acute Treatment of Migraine
The purpose of this study is to evaluate the long-term safety of BHV-3500/vazegepant intranasal in the acute treatment of migraine. BHV-3500, formerly "vazegepant", is now referred to as "zavegepant" (za ve' je pant).
- Trial name
- NCT04408794
- Testing
- Zavegepant (BHV-3500)
- Where
- 67 sites in United States
- Volunteers
- 974 people
- Sponsor
- Pfizer
Acute Migraine
A Study of K-645 in the Treatment of Multiple Migraine Attacks
This is a multicenter, randomized, double-blind, placebo-controlled, 3-period crossover study to evaluate the safety, tolerability, and efficacy of two dose levels of K-645 in the treatment of patients with acute migraine.
- Trial name
- NCT07116499
- Testing
- K-645 dose level 1, K-645 dose level 2
- Where
- 18 sites in United States
- Volunteers
- 134 people
- Sponsor
- TriGemX Bio, Inc.
Acute Migraine
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
This is a long-term safety study to evaluate the safety and tolerability of intermittent use of elismetrep in the acute treatment of migraine attacks.
- Trial name
- NCT07674654
- Testing
- Elismetrep
- Where
- 113 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- TriGemX Bio, Inc.
Migraine Disorders
Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS Versus Placebo in the Treatment of a Single Attack of Acute Migraine Headache
Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS in patients with a single acute migraine attack with or without aura
- Trial name
- NCT02198339
- Testing
- BIBN 4096 BS
- Volunteers
- 126 people
- Sponsor
- Boehringer Ingelheim
Migraine Headache
Study in Participants With Acute Migraines Headaches
This is a Phase 2, multicenter, randomized, double-blind, placebo and active comparator-controlled study of LY2590443 in approximately 200 participants with migraines.
- Trial name
- NCT00804973
- Testing
- LY2590443, Sumatriptan
- Where
- 19 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Migraine Headache
Zomig - Treatment of Acute Migraine Headache in Adolescents
The purpose of this study is to investigate if Zomig® Nasal Spray will help children (age 12-17 years) with migraine headaches feel better.
- Trial name
- TEENZ (NCT01211145)
- Testing
- Zolmitriptan
- Where
- 74 sites in United States, Estonia and 6 more
- Volunteers
- 1,653 people
- Sponsor
- AstraZeneca
Migraine Headaches
To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine Headaches
To determine the efficacy of the Trexima versus placebo as assessed by pain relief and the incidences of photophobia, phonophobia and nausea at 2 hours after treatment as the primary endpoints.
- Trial name
- NCT00433732
- Testing
- sumatriptan, naproxen sodium
- Where
- 2 sites in United States
- Volunteers
- 1,400 people
- Sponsor
- POZEN
Migraines
Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031)
The purpose of the study is to assess the safety and efficacy of telcagepant (MK-0974) in acute treatment of multiple migraine attacks with or without aura.
- Trial name
- NCT00483704
- Testing
- Telcagepant 140 mg, Talcagepant 280 mg
- Volunteers
- 1,935 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Migraine, Headache, Episodic Migraine
Occipital Blocks for Acute Migraine
Migraine affects 10-28% of children and adolescents and yet 20-30% of patients are ineffectively treated with current oral and nasal options.
- Trial name
- NCT03526874
- Testing
- Lidocaine 4% Topical Application Cream [LMX 4], Lidocaine Hydrochloride 2 mg/mL Injectable Solution, Normal Saline
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Children's Hospital of Philadelphia
Migraine, Acute Treatment of Migraine
Nerivio Long-term Usage in Patients With Migraine
This is a post-marketing real-world evidence study investigates long-term treatment with the Remote Electrical Neuromodulation (REN) wearable Nerivio device over 3 consecutive years in patients with migraine.
- Trial name
- NCT06738056
- Testing
- Nerivio
- Where
- United States
- Volunteers
- 244 people
- Sponsor
- Theranica